Routine use of vasoactive drugs in circulatory shock is not recommended, as they may worsen perfusion failure; selective use is mandatory.
Supports selective adrenergic agonist use in shock only; leaves open RCTs confirming nutritive flow benefits.
Reduction of effective blood flow represents the primary disturbance accounting for circulatory shock. Four categories of circulatory shock are identified: cardiogenic, hypovolemic, distributive, and obstructive. The pharmacology and clinical implications for treatment of shock with vasoactive drugs are reviewed in this context. Except for epinephrine, when it is used for treatment of anaphylactic shock, there is no specific indication for the routine use of alpha- or beta-adrenergic receptor agonists. These agents may increase blood pressure or cardiac output, but nutritive flow is not necessarily improved. Comparable limitations are observed with alpha-adrenergic receptor blocking agents. However, selective effects on the myocardium and on the resistance, exchange, and capacitance vessels may be advantageous as an interim and complementary measure. Since vasoactive drugs frequently intensify the fundamental defect accounting for perfusion failure, their selective rather than routine employment is mandatory.
No takes yet. Share an insight, caveat, or question.
Max Harry Weil (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: